Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

enGene Therapeutics is a promising investment opportunity due to the convenience and safety of their gene therapy, detalimogene, for treating Non-Muscle Invasive Bladder Cancer (NMIBC). The upcoming 12-month CR readout from Cohort 1 and polidocanol bladder rinse cohort data serve as critical milestones for the company, along with potential BLA filing initiation and approval decision in 2027. While there are risks, such as R&D setbacks and competition, the potential upside for pipeline success and product sales make it a compelling investment choice. Financial data shows an increase in net loss, primarily due to higher expenses related to ongoing clinical trials and preparation for BLA submission.

Bears say

enGene Therapeutics is facing a number of challenges that could potentially hinder the success and marketability of their lead product, detalimogene voraplasmid. The recent clinical data from the ongoing LEGEND Phase 2 trial has shown a decline in efficacy compared to previous interim analyses, causing concern among investors. Additionally, the company has had to make significant workforce reductions and has put enrollment plans on hold, potentially delaying commercialization. While detalimogene has unique advantages in its mode of administration and safety profile, it falls short of contemporary benchmarks and may struggle to gain a significant share of the increasingly competitive NMIBC market.

ENGN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 8 analysts, ENGN has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.